Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab

A single-center experience

Akinao Okamoto, Masamitsu Yanada, Yoko Inaguma, Masutaka Tokuda, Satoko Morishima, Tadaharu Kanie, Yukiya Yamamoto, Motohiro Tsuzuki, Yoshiki Akatsuka, Shuichi Mizuta, Masataka Okamoto, Nobuhiko Emi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The beneficial effect of rituximab for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been demonstrated by several randomized controlled trials. To clarify whether results for selected patient populations also apply to unselected patients, we analyzed long-term outcomes for all the 277 consecutive adults diagnosed with de novo DLBCL in a single center between 1998 and 2008. The study population included 147 and 130 patients diagnosed before (Cohort A) and after the advent of rituximab (Cohort B). Progression-free survival (PFS) was significantly better for Cohort B than for Cohort A (P = 0.005). For patients age 60 or younger, PFS did not differ significantly between Cohort A and Cohort B (P = 0.329), but for patients over 60, Cohort B showed superior PFS (P = 0.002). Patients with high or high-intermediate risk according to the International Prognostic Index score showed less improvement in PFS than did those with low or low-intermediate risk primarily because of still unfavorable outcomes of patients with poor performance status. These results indicate that the advent of rituximab has significantly improved outcome for unselected patients with DLBCL, and that improvement was greater for older patients. Further investigations are warranted in the hope of improving outcomes for younger patients with DLBCL.

Original languageEnglish
Pages (from-to)74-80
Number of pages7
JournalHematology
Volume18
Issue number2
DOIs
Publication statusPublished - 01-03-2013

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival
Rituximab
Population
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Okamoto, Akinao ; Yanada, Masamitsu ; Inaguma, Yoko ; Tokuda, Masutaka ; Morishima, Satoko ; Kanie, Tadaharu ; Yamamoto, Yukiya ; Tsuzuki, Motohiro ; Akatsuka, Yoshiki ; Mizuta, Shuichi ; Okamoto, Masataka ; Emi, Nobuhiko. / Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab : A single-center experience. In: Hematology. 2013 ; Vol. 18, No. 2. pp. 74-80.
@article{0edc729ca07e4f7f8d1d2fdc913ea0c6,
title = "Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: A single-center experience",
abstract = "The beneficial effect of rituximab for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been demonstrated by several randomized controlled trials. To clarify whether results for selected patient populations also apply to unselected patients, we analyzed long-term outcomes for all the 277 consecutive adults diagnosed with de novo DLBCL in a single center between 1998 and 2008. The study population included 147 and 130 patients diagnosed before (Cohort A) and after the advent of rituximab (Cohort B). Progression-free survival (PFS) was significantly better for Cohort B than for Cohort A (P = 0.005). For patients age 60 or younger, PFS did not differ significantly between Cohort A and Cohort B (P = 0.329), but for patients over 60, Cohort B showed superior PFS (P = 0.002). Patients with high or high-intermediate risk according to the International Prognostic Index score showed less improvement in PFS than did those with low or low-intermediate risk primarily because of still unfavorable outcomes of patients with poor performance status. These results indicate that the advent of rituximab has significantly improved outcome for unselected patients with DLBCL, and that improvement was greater for older patients. Further investigations are warranted in the hope of improving outcomes for younger patients with DLBCL.",
author = "Akinao Okamoto and Masamitsu Yanada and Yoko Inaguma and Masutaka Tokuda and Satoko Morishima and Tadaharu Kanie and Yukiya Yamamoto and Motohiro Tsuzuki and Yoshiki Akatsuka and Shuichi Mizuta and Masataka Okamoto and Nobuhiko Emi",
year = "2013",
month = "3",
day = "1",
doi = "10.1179/1607845412Y.0000000045",
language = "English",
volume = "18",
pages = "74--80",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

Okamoto, A, Yanada, M, Inaguma, Y, Tokuda, M, Morishima, S, Kanie, T, Yamamoto, Y, Tsuzuki, M, Akatsuka, Y, Mizuta, S, Okamoto, M & Emi, N 2013, 'Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: A single-center experience', Hematology, vol. 18, no. 2, pp. 74-80. https://doi.org/10.1179/1607845412Y.0000000045

Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab : A single-center experience. / Okamoto, Akinao; Yanada, Masamitsu; Inaguma, Yoko; Tokuda, Masutaka; Morishima, Satoko; Kanie, Tadaharu; Yamamoto, Yukiya; Tsuzuki, Motohiro; Akatsuka, Yoshiki; Mizuta, Shuichi; Okamoto, Masataka; Emi, Nobuhiko.

In: Hematology, Vol. 18, No. 2, 01.03.2013, p. 74-80.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab

T2 - A single-center experience

AU - Okamoto, Akinao

AU - Yanada, Masamitsu

AU - Inaguma, Yoko

AU - Tokuda, Masutaka

AU - Morishima, Satoko

AU - Kanie, Tadaharu

AU - Yamamoto, Yukiya

AU - Tsuzuki, Motohiro

AU - Akatsuka, Yoshiki

AU - Mizuta, Shuichi

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The beneficial effect of rituximab for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been demonstrated by several randomized controlled trials. To clarify whether results for selected patient populations also apply to unselected patients, we analyzed long-term outcomes for all the 277 consecutive adults diagnosed with de novo DLBCL in a single center between 1998 and 2008. The study population included 147 and 130 patients diagnosed before (Cohort A) and after the advent of rituximab (Cohort B). Progression-free survival (PFS) was significantly better for Cohort B than for Cohort A (P = 0.005). For patients age 60 or younger, PFS did not differ significantly between Cohort A and Cohort B (P = 0.329), but for patients over 60, Cohort B showed superior PFS (P = 0.002). Patients with high or high-intermediate risk according to the International Prognostic Index score showed less improvement in PFS than did those with low or low-intermediate risk primarily because of still unfavorable outcomes of patients with poor performance status. These results indicate that the advent of rituximab has significantly improved outcome for unselected patients with DLBCL, and that improvement was greater for older patients. Further investigations are warranted in the hope of improving outcomes for younger patients with DLBCL.

AB - The beneficial effect of rituximab for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been demonstrated by several randomized controlled trials. To clarify whether results for selected patient populations also apply to unselected patients, we analyzed long-term outcomes for all the 277 consecutive adults diagnosed with de novo DLBCL in a single center between 1998 and 2008. The study population included 147 and 130 patients diagnosed before (Cohort A) and after the advent of rituximab (Cohort B). Progression-free survival (PFS) was significantly better for Cohort B than for Cohort A (P = 0.005). For patients age 60 or younger, PFS did not differ significantly between Cohort A and Cohort B (P = 0.329), but for patients over 60, Cohort B showed superior PFS (P = 0.002). Patients with high or high-intermediate risk according to the International Prognostic Index score showed less improvement in PFS than did those with low or low-intermediate risk primarily because of still unfavorable outcomes of patients with poor performance status. These results indicate that the advent of rituximab has significantly improved outcome for unselected patients with DLBCL, and that improvement was greater for older patients. Further investigations are warranted in the hope of improving outcomes for younger patients with DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=84875735551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875735551&partnerID=8YFLogxK

U2 - 10.1179/1607845412Y.0000000045

DO - 10.1179/1607845412Y.0000000045

M3 - Article

VL - 18

SP - 74

EP - 80

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 2

ER -